一例血凝酶制剂致低纤维蛋白原血症患者的药学监护

目的: 探讨蛇毒血凝酶制剂在肝硬化患者应用中的药学监护。方法: 临床药师参与一例肝硬化伴低纤维蛋白原血症患者的治疗,根据国家药品不良反应监测中心的评价标准进行药学评价,判断为蛇毒血凝酶制剂所致不良反应,建议避免使用相关药物并对该患者进行药学监护。结果: 临床药师利用专业知识提供合理化用药建议,被临床医生接纳,及时有效地处理药物不良反应,使患者得到有效治疗后顺利出院。结论: 临床药师参与肝硬化患者的治疗过程,开展药学服务,可提供合理、有效的用药建议以确保患者用药安全。

Pharmaceutical care on one case of hypobrinogenemia induced by hemocoagulase

AIM: To investigate the pharmaceutical care of patients with cirrhosis decompensated in the application of hemocoagulase. METHODS: By participating in the treatment of 1 case of cirrhosis with hypofibrinogenemia, clinical pharmacist conducted a pharmacy evaluation according to the evaluation criteria of the National Center for ADR Monitoring. The result indicated an ADR caused by the hemocoagulase. It is recommended to avoid using the relevant drugs and to perform pharmacological monitoring on the patient.RESULTS: Clinical pharmacist provided rational suggestions with professional knowledges, accepted by clinicians, timely and effective treatment of adverse drug reactions, so that patients can be discharged after effective treatment. CONCLUSION: Clinical pharmacists participate in the treatment process of patients with cirrhosis and carry out pharmacy services, which can provide reasonable and effective medication recommendations to ensure the safety of patients.